Downstream Processing Featured Articles
-
Theraclone Sciences Secures $14M In Additional Financing
3/25/2013
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, recently announced a $14M financing. $8M in equity is committed from existing investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo in a Series B Extension, bringing the total round to $50M.
-
NIST Study Suggests Carbon Nanotubes May Protect DNA From Oxidation
11/14/2012
Researchers at the National Institute of Standards and Technology (NIST) have provided evidence in the laboratory that single-wall carbon nanotubes (SWCNTs) may help protect DNA molecules from damage by oxidation.
-
Additional Details Concerning Issue Of Shares To Johnson & Johnson Development Corporation As Part Of The Daratumumab Agreement
8/30/2012
Genmab A/S announced recently additional details concerning the subscription of shares by Johnson & Johnson Development Corporation (JJDC) as part of the global license and development agreement for daratumumab (HuMax-CD38) between Genmab (see Genmab's Company Announcement 20) and Janssen Biotech, Inc., one of the Janssen Pharmaceutical companies of Johnson & Johnson.
-
Is There An Enzyme In Your Future?
8/25/1998
A method for reducing the chemical steps in vitamin C synthesis from six to two underscores the growing importance of enzymes in organic synthesis...
-
Mayo Clinic Uses New Approach To Reverse Multiple Sclerosis In Mice Models
6/28/2012
Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients.
-
Next Generation Single-Use Bioreactor Improves Cell Culture Performance
9/18/2013
The next-generation HyPerforma Single-Use Bioreactor has been redesigned to provide improved ergonomics while retaining traditional stainless steel bioreactor design principles to enhance cell culture performance.
-
Company Recognized For Outstanding Contributions To The Pharmaceutical Sciences
5/30/2012
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Scientists (AAPS) has awarded its 2012 Excellence in Ligand Binding Assays Award to the Bioanalytical Development group from Morphotek for their abstract, “Development and Validation of a Pharmacokinetic Assay on the Gyrolab Platform for Use in Phase II/III Clinical Studies.” The award was presented at the AAPS 2012 National Biotechnology Conference held May 21-23 in San Diego.
-
Breast Cancer Clinical Trial To Test Combination Of Heat Shock Protein Inhibitor And Hormonal Therapy
5/22/2012
Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. By Nicole Giese Rura
-
Laser Spotlight Reveals Machine 'Climbing' DNA
10/26/2012
The experiments, reported in this week's Science, use laser light to generate very bright patches close to single cells. When coupled with fluorescent tags this 'spotlight' makes it possible to image the inner workings of cells fast enough to see how the molecular machines inside change size, shape, and composition in the presence of DNA.
-
Finesse Solutions Launches TruBio DV 4.5 Bioreactor Control Software For Its Novel SmartParts Component Platform
3/18/2013
Finesse Solutions, Inc., Santa Clara, CA, a manufacturer of measurement and control solutions for life science process applications, announced the release of TruBio DV version 4.5 bioreactor control software that leverages its new SmartParts components.